NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

83% of Kids Tolerate More Peanut with VIASKIN Patch in Landmark Study

DBV Technologies reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety.

83% of Kids Tolerate More Peanut with VIASKIN Patch in Landmark Study
Photo by Vladislav Nikonov on Unsplash
Already have an account? Sign in.
03/02/2026 · 11:09 AM
DBVT
/ Don’t stop at just one post.

Related↓

Peanut Allergy Patch Shows 47% Success Rate in Children
12/16/2025 · 4:38 PM

Peanut Allergy Patch Shows 47% Success Rate in Children

DBV Technologies' (DBVT) VIASKIN Peanut patch shows significant success in treating peanut allergies in children aged 4-7, with nearly half of participants responding positively after one year.

/ Subscriber only
/ Read more

Feed↓

Evolus shares fall after FDA calls Jeuveau Instagram post misleading
10/02/2026 · 4:04 PM

Evolus shares fall after FDA calls Jeuveau Instagram post misleading

The FDA says an Evolus Instagram post overstated Jeuveau benefits and downplayed risks. The firm has 15 working days to respond.

/ Subscriber only
Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion
Featured/ 10/02/2026 · 3:45 PM

Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion

Novartis will pay $575 million upfront for worldwide rights to Abogen's mRNA T-cell engager, plus up to $7.2 billion in milestones.

/ Subscriber only
20 New Planet Satellites Reach Orbit on SpaceX’s Transporter-18
10/02/2026 · 2:42 PM

20 New Planet Satellites Reach Orbit on SpaceX’s Transporter-18

Planet Labs put 20 satellites in orbit on Oct. 1, 2026, including a Google TPU prototype, Tanager-2 methane sensor, and 18 SuperDoves.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe